获得性免疫缺陷综合征患者应用艾博韦泰致药物不良反应报告及危险因素分析  

Risk factors analysis and report on adverse drug reactions of albuvirtide in acquired immunodeficiency syndrome patients

作　　者：邱新野[1] 朱晓虹[1] 尹月[2] 刘炜 林阳[3] QIU Xin-ye;ZHU Xiao-hong;YIN Yue;LIU Wei;LIN Yang(Department of Pharmacy,Beijing Youan Hospital,Capital Medical University,Beijing 100069,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Pharmacy y Peking University Cancer Hospital&Institute,Beijing 100142,China;Department of Pharmacy,Beijing Anzhen Hospital,Capital Medical University,Beijing 100029,China)

机构地区：[1]首都医科大学附属北京佑安医院药学部,北京100069 [2]北京大学肿瘤医院暨北京市肿瘤防治研究所药剂科,恶性肿瘤发病机制及转化研究教育部重点实验室,北京100142 [3]首都医科大学附属北京安贞医院药事部,北京100029

出　　处：《中国临床药理学杂志》2022年第5期457-459,共3页The Chinese Journal of Clinical Pharmacology

基　　金：首都医科大学附属北京佑安医院2021年度院内中青年人才孵育基金资助项目(YNKTGL2021002)。

摘　　要：目的探讨获得性免疫缺陷综合征(AIDS)患者使用艾博韦泰致药物不良反应的特点,分析危险因素,为临床药物警戒及合理用药提供参考。方法采用回顾性研究方法,统计及分析2020年8月至2021年8月在住院并使用艾博韦泰治疗的AIDS患者基本信息、实验室检查、艾博韦泰使用情况、药物不良反应信息及转归等。结果共纳入99例使用艾博韦泰治疗的AIDS患者,15例发生药物不良反应,药物不良反应发生率为15.15%,最常累及器官为消化系统及皮肤。发生药物不良反应患者经对症治疗后症状全部状好转或痊愈。相关因素分析显示,年龄≥44岁(OR=18.74)、合并既往药物过敏史(OR=158.77)及基础谷草转氨酶(GOT)≥31 U·L^(-1)(OR=11.35)为AIDS患者使用艾博韦泰发生药物不良反应的独立危险因素(P<0.05)。结论艾博韦泰安全性较高,但治疗期间应加强重点人群监测,包括中老年、合并既往药物过敏史及基础GOT较高的AIDS患者。Objective To explore the characteristics of adverse drug reactions of albuvirtide in acquired immunodeficiency syndrome(AIDS) patients and analyze the risk factors, to provide reference for clinical pharmacovigilance and rational use of drugs. Methods A retrospective analysis. Date and analyze the basic information, laboratory test indexes, use of albuvirtide, adverse drug reactions and outcomes of AIDS patients hospitalized and treatment with albuvirtide in our hospital from August 2020 to August 2021. Results Totally 99 AIDS patients were involved, 15 patients had adverse drug reactions, and the incidence of adverse reactions was 15.15%. The digestive system and the skin adverse drug reactions were the most commonly. All of the patients with drug reactions were cured. Correlation analysis showed that age ≥ 44 years(OR=18.74), AIDS patients with a history of drug allergy(OR= 158.77) and basal glutamic-oxaloacetic transaminase(GOT) ≥31 U·L^(-1)(OR=11.35) were independent risk factors for adverse drug reactions in using albuvirtide for AIDS patients(P<0.05). Conclusion Albuvirtide is safe, but the monitoring of key groups should be strengthened during the treatment, including middle-aged and elderly patients, AIDS patients with a history of drug allergy and high basal GOT.

关 键 词：艾博韦泰 获得性免疫缺陷综合征 药物不良反应 危险因素 

分 类 号：R97[医药卫生—药品]